The type 2 diabetes (T2D) therapy market is forecast to expand through 2032, supported by polypharmacy and growing use of later-line therapies; however, loss of exclusivity for several key T2D…
Metformin is the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective…
Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Therefore, it is unsurprising that insulins…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 1 diabetes patient populations covering 171 countries and more…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
The next 10 years will be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to increase. Therapies in the late-phase pipeline represent drug classes…